Abstract Body

Drug-resistant tuberculosis (TB) is a global public health crisis, with 480,000 cases occurring annually and 190,000 dying of this disease. Extensively drug-resistant (XDR) TB involves resistance to the most potent first-line and second-line drugs to treat TB and has been reported from over 100 countries. Although the End TB Strategy calls for universal access to drug-susceptibility testing (DST), less than one-third of bacteriologically-confirmed TB cases had DST done, leading to massive diagnostic gaps. Among those diagnosed with MDR-TB, inadequate access to second-line TB drugs – in part due to bottlenecks created by centralized models of MDR-TB care – result in large treatment gaps. Current treatment regimens for MDR-TB are lengthy (minimum 18-24 months), costly (10-15 times the cost of drug-susceptible TB), have numerous side effects and result in cure for less than 50% of patients. Taken together, these major shortfalls in diagnosis, treatment and outcomes create a perfect storm for perpetuating the cycle of MDR-TB transmission and epidemic spread. Although transmission of MDR-TB strains has been well-described in outbreak settings for decades, the role of transmission in widespread epidemics is less understood. Characterizing the role of transmission is critical for informing public health interventions which, until now, have focused primarily on preventing acquired resistance (though the DOTS strategy) and far less on preventing transmission (through infection control strategies). In settings that have begun to address transmission prevention, efforts have focused on healthcare settings, with little attention to communities, where over 50% of transmission may be occurring. Known and novel interventions to halt transmission include universal access to DST, rapid initiation of effective treatment, monitoring for emergence of resistance, screening of close contacts and environmental controls (e.g., germicidal UV, improving ventilation, reducing crowding). This talk will review the global epidemiology of TB, the growing data on the role of transmission in drug-resistant TB epidemics, and potential interventions aimed at reducing transmission.